Investigating how specific proteins can be targeted for new drug development
Official title: Profiling the specificity of SPI1 and SPIB activity for drug discovery
Funded at Georgia State University · NIH-11032110 · Data updated 2026-11-12
This study is looking at two proteins that help make blood cells and are connected to some rare diseases, with the goal of finding new ways to create medicines that could help people with conditions like leukemia and autoimmune diseases.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | December 15, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $156,000 |
| NIH project number | 1R03TR004842-01A1 |
| Project ID | NIH-11032110 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with rare hematopoietic diseases such as leukemias, lymphomas, or autoimmune disorders.
✕Less likely to help
Patients with common, non-hematopoietic conditions or those not affected by rare diseases may not benefit from this research.
What this research studies
This research focuses on understanding the roles of two important proteins, SPI1 and SPIB, which are involved in blood cell formation and are linked to various rare diseases. By profiling how these proteins function, the research aims to identify new ways to develop drugs that can effectively target them. The approach includes using small molecules to modulate the activity of these proteins, potentially leading to innovative treatments for conditions like leukemias and autoimmune diseases. Patients may benefit from new therapeutic options that arise from this targeted drug discovery process.
Why it matters
Potential benefit: If successful, this research could lead to the development of new drugs that specifically target rare diseases related to blood cell formation.
How similar studies have gone: Other research has shown promise in targeting transcription factors for drug discovery, suggesting that this approach could yield significant advancements.
Where this research is happening
-
Georgia State University
Atlanta, United States Active
Researchers
- Principal investigator: Poon, Gregory Man Kai — Georgia State University
- Study coordinator: Poon, Gregory Man Kai
Related research
Other NIH-funded projects on the same topics.
-
Exploring how Neisseria gonorrhoeae uses nutrients and host sugars to thrive
A study to understand how the gonorrhea bacteria grab nutrients from the human host and how it interacts with sugars on our cells to help design better treatments.
-
Environmental and sanitation improvements with a smartphone app
A low-cost smartphone tool helps US cities and households report sanitation problems to prevent illness and costly repairs.
-
Vaccine study in mice to protect against gonorrhea using a new OMV-based approach
Researchers are testing an OMV-based vaccine in mouse models to block Neisseria gonorrhoeae infection by targeting key bacterial proteins.
-
Vaccine design to protect against future coronaviruses
A new vaccine concept aims to protect people by targeting multiple coronavirus lineages likely to cause future pandemics.
-
Neuro-Symbolic Models for Explaining Epidemic Dynamics (EpiXplain)
A new modeling framework will blend AI reasoning with symbols to help explain and forecast how diseases spread, considering biology, behavior, mobility, and interventions relevant to patients.
-
Frataxin's role in protecting the liver from MASLD-related injury
This grant studies how a mitochondrial helper protein, frataxin, affects liver damage in people with MASLD (a common liver disease), with the aim of finding new ways to prevent or reduce injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.